IDXX SEC Filings

IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on May 15, 2026, detailing significant corporate governance changes approved by shareholders at the May 12, 2026 annual meeting. The primary focus is the amendment to the Certificate of Incorporation and By-Laws to declassify the Board of Directors over a three-year period, with all directors to be elected annually starting in 2029. This move enhances shareholder oversight and aligns with modern corporate governance trends, making the board more directly accountable to shareholders. Furthermore, shareholders approved amendments granting a right to call a special meeting to those holding at least 25% of the company's capital stock continuously for at least one year. This provides a critical mechanism for shareholders to address urgent matters outside of the regular annual meeting schedule, increasing their influence and ability to effect change. The report also confirms the ratification of PricewaterhouseCoopers LLP as the independent auditor and the advisory approval of executive compensation, alongside the election of three Class II directors.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on May 5, 2026, to report its financial results for the quarter ended March 31, 2026. The filing primarily furnished a press release containing these results, which is attached as Exhibit 99.1. Investors should note that this information is being furnished under Item 2.02 and is not considered "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings, unless specifically stated. While the specific financial figures from the press release are not detailed within the 8-K text itself, this report serves as the official notification to the market of IDEXX's first-quarter performance. Investors seeking detailed insights into revenue, profitability, and any forward-looking statements will need to refer to the furnished press release (Exhibit 99.1).

IDEXX Laboratories, Inc. reported robust financial performance for the first quarter of 2026, demonstrating significant revenue growth and improved profitability. Total revenue increased by 14.3% year-over-year to $1.14 billion, driven by strong demand across all operating segments, particularly within the Companion Animal Group (CAG). The company achieved a 15.9% increase in gross profit, expanding the gross profit margin by 100 basis points due to recurring revenue growth, operational efficiencies, and effective price realization, despite inflationary pressures. Net income saw a substantial rise of 14.8% to $278.4 million, translating to diluted earnings per share of $3.47, up from $2.96 in the prior year. The company's balance sheet remains solid with $200.5 million in cash and cash equivalents and $718.2 million in available borrowing capacity under its credit facility. Significant stock repurchase activity continued, reflecting a commitment to returning value to shareholders. The company provided a positive outlook, anticipating favorable currency impacts for the remainder of the year.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on March 26, 2026, to report the departure of Dr. Nimrata Hunt, Executive Vice President of Global Strategy and Commercial, effective April 13, 2026. This departure was a mutual agreement, and Dr. Hunt will provide advisory services until July 13, 2026. The company has entered into a separation agreement that outlines the terms of her exit and advisory role. Investors should note the financial implications of Dr. Hunt's departure, including a separation package totaling approximately $2.24 million in salary continuation and target bonuses, along with COBRA premium costs, transition assistance, and tax/financial planning reimbursements. The company is classifying this as a termination without cause. The agreement also includes standard clauses like general release of claims, non-disparagement, and ongoing adherence to restrictive covenants. This filing primarily addresses a significant executive transition and associated costs.

IDEXX Laboratories, Inc. (IDXX) reported strong financial performance for the year ended December 31, 2025, with total revenue reaching $4.30 billion, a 10.4% increase year-over-year. The Companion Animal Group (CAG) remains the primary revenue driver, contributing $3.95 billion, up 10.6% driven by strong recurring revenue from consumables and reference laboratory services. The company is strategically investing in Artificial Intelligence (AI) to enhance its diagnostic products and services, aiming to provide veterinarians with advanced tools for pet healthcare. Operational efficiency and strategic pricing contributed to a 11.8% increase in gross profit, with the gross profit margin improving to 61.8%. Despite inflationary pressures affecting product and labor costs, IDEXX demonstrated effective cost management, leading to a 20.5% increase in income from operations to $1.36 billion. The company also continued its share repurchase program, reflecting its commitment to returning value to shareholders. Looking ahead, IDEXX anticipates continued growth, though it acknowledges potential headwinds from macroeconomic factors and supply chain challenges, which it plans to manage through proactive strategies.

IDEXX Laboratories, Inc. (IDXX) announced a change in its Board of Directors composition. Ms. M. Anne Szostak has notified the company of her intention to retire from the Board, effective immediately after the 2026 Annual Meeting of Stockholders on May 12, 2026. Her retirement is not due to any disagreements concerning the company's operations or policies, indicating a smooth transition. The company expressed gratitude for her significant contributions and leadership since 2012. The Board will reduce the size of the Class III directors upon Ms. Szostak's retirement. This reduction, however, will be offset by the previously announced appointment of Michael G. Erickson, PhD, as a Class II director, also effective immediately following the 2026 Annual Meeting. Investors should note that these changes are procedural and do not appear to reflect any underlying issues with the company's performance or governance.

IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report, filed on February 2, 2026, primarily serves to furnish the accompanying press release containing these financial details. Investors should note that the information provided in this filing is furnished under Item 2.02 and is not considered "filed" for purposes of Section 18 of the Exchange Act, nor is it automatically incorporated into other filings unless specifically referenced. The key takeaway for investors is the announcement of the company's performance for the recently concluded fiscal year and the final quarter. While the specific financial figures are contained within the furnished press release (Exhibit 99.1), this 8-K filing formally brings those results into the public domain. Investors interested in IDXX's operational and financial condition should refer to the press release for detailed metrics, revenue figures, profitability, and any forward-looking statements or guidance.

IDEXX Laboratories, Inc. (IDXX) announced a CEO transition plan, with current President and CEO Jonathan (Jay) Mazelsky stepping down on May 12, 2026, and transitioning to the role of Executive Chair of the Board. He will retire in May 2027. Dr. Michael Erickson, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will assume the roles of President and CEO and join the Board. Dr. Erickson has a strong background in healthcare technology and innovation, having been with IDEXX since 2011 and previously consulting with McKinsey & Company. This leadership change is designed to ensure a smooth handover and leverage Dr. Erickson's extensive experience within the company. The filing also details the compensation arrangements for both Mr. Mazelsky in his new role and Dr. Erickson as he takes on the CEO position. Dr. Erickson's compensation package includes a $1 million base salary, a target bonus of 120% of base salary, and a significant long-term incentive equity award valued at no less than $7.8 million for fiscal year 2026, comprising stock options and performance-based RSUs. Mr. Mazelsky will receive an annual base salary of $1,150,000 as Executive Chair, along with specific bonus and equity arrangements for fiscal year 2026. Both executives have entered into new agreements outlining terms for potential termination scenarios and change-in-control events, ensuring clarity and continuity.

IDEXX LABORATORIES INC /DE (IDXX) filed an 8-K on November 12, 2025, detailing an amendment to its credit agreement. This amendment, specifically Amendment No. 2 to the Fourth Amended and Restated Credit Agreement, primarily extends the maturity dates for its revolving credit facility and introduces a new term loan facility. The revolving credit facility will now mature five years from the amendment's closing date, while the new term loan facility will mature three years from closing. This strategic move enhances the company's financial flexibility and extends its debt maturity profile. The total credit facility remains at $1.0 billion for the revolving line, with an additional $250 million for the term loan, and includes the option to incur up to an additional $250 million in incremental commitments. Borrowings can be used for general corporate purposes, providing management with resources for ongoing operations and potential strategic initiatives.

IDEXX Laboratories, Inc. (IDXX) has filed a Form 8-K report on November 3, 2025, to announce its financial results for the third quarter ended September 30, 2025. The report primarily serves to furnish a press release detailing these results, which is attached as Exhibit 99.1. This filing does not contain extensive new operational details but rather directs investors to the accompanying press release for a comprehensive overview of the company's performance during the quarter. Investors should refer to the press release (Exhibit 99.1) for specific financial metrics, including revenue, earnings per share, and any forward-looking guidance or commentary provided by management. While the 8-K itself is a procedural filing, the furnished press release is the key document for understanding IDEXX's recent financial health and future outlook.

IDEXX Laboratories, Inc. reported strong financial results for the nine months ended September 30, 2025. Total revenue increased by 9.2% to $3.21 billion, driven by robust performance in its Companion Animal Group (CAG) segment, which saw a 9.3% revenue increase. The company demonstrated solid operational execution, with income from operations rising by 20.5% to $1.04 billion and net income growing by 20.8% to $811.3 million. Diluted EPS also saw a significant increase, reaching $9.99 for the nine-month period. The company's strategic focus on recurring revenue streams, particularly within its CAG Diagnostics recurring revenue category, continues to be a key driver of growth and profitability, with this segment showing a 7.8% increase. Financial health remains strong, with ample liquidity and a healthy balance sheet, supported by consistent operating cash flow generation. The company also continued its commitment to shareholder returns through active share repurchase programs. For the third quarter of 2025, IDEXX maintained its positive momentum, with total revenue up 13.3% year-over-year to $1.11 billion, and income from operations increasing by 16.8% to $354.8 million. The CAG segment once again led the growth, with a 13.5% revenue increase, bolstered by strong performance in IDEXX VetLab consumables and reference laboratory diagnostic services. Despite inflationary pressures and the impact of foreign currency fluctuations, IDEXX successfully expanded its gross profit margin and maintained disciplined operating expense management, leading to improved profitability. The company's outlook for the remainder of the year appears positive, with favorable currency impacts projected.

IDEXX Laboratories, Inc. (IDXX) has announced a change to its Board of Directors through an 8-K filing dated October 7, 2025. Effective October 6, 2025, Karen Peacock was elected as an independent Class I Director. This appointment increases the total number of directors from ten to eleven and strengthens the board's expertise by adding Ms. Peacock to both the Compensation and Talent Committee and the Finance Committee. Ms. Peacock's election is a strategic move to enhance board oversight and expertise in key areas relevant to the company's ongoing operations and strategic initiatives.

IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K to announce its financial results for the second quarter ended June 30, 2025. The report primarily furnishes a press release detailing these results, which investors should review for comprehensive financial performance insights. This filing does not contain new audited financial statements but serves as the official channel for disseminating the company's quarterly earnings information as of August 4, 2025.

IDEXX LABORATORIES, INC. (IDXX) reported a strong second quarter for 2025, demonstrating robust revenue growth and improved profitability. Total revenue increased by 10.6% year-over-year to $1.11 billion for the three months ended June 30, 2025, driven by solid performance across its key segments, particularly the Companion Animal Group (CAG). This growth was fueled by strong recurring revenue from diagnostics, consumables, and services, along with a significant increase in instrument placements. The company's operational efficiency is evident in the expansion of its gross profit margin, which increased by 90 basis points to 62.6%, driven by higher volumes, price realization, and productivity improvements. While operating expenses saw an increase primarily in sales and marketing, a significant decrease in general and administrative expenses, due to a one-time litigation charge in the prior year, led to a substantial 41.4% increase in income from operations to $373.0 million. This performance highlights IDEXX's ability to grow its top line while managing costs effectively, presenting a positive financial outlook for investors.

IDEXX Laboratories, Inc. (IDXX) announced a significant change to its Board of Directors with the election of Joseph L. (Jay) Hooley as an independent Class III Director, effective July 10, 2025. This appointment also includes his membership on the Audit Committee and Governance and Corporate Responsibility Committee. To accommodate Mr. Hooley's addition, the Board's size has been expanded from nine to ten directors, with an increase in Class III Directors from three to four. Mr. Hooley, an independent director, has no reported related party transactions with the Company. His compensation will align with that of other non-employee Directors, with prorated cash fees for the current quarter and prorated equity grants (deferred stock units or restricted stock units and stock options) to be issued on September 1, 2025. He will also be eligible to participate in the Company's Director Deferred Compensation Plan. The company issued a press release on July 10, 2025, detailing this appointment, which is furnished as an exhibit to this filing.

IDEXX LABORATORIES INC /DE (IDXX) has filed an 8-K report detailing significant amendments to its corporate governance documents, effective May 7, 2025. The company has eliminated its Series A Junior Participating Preferred Stock, returning these shares to undesignated preferred stock status. More critically for investors, the company's Certificate of Incorporation and By-Laws have been amended to remove supermajority voting requirements and to allow for officer exculpation, aligning with recent Delaware law changes. These changes were approved by the Board of Directors and subsequently ratified by stockholders at the Annual Meeting held on May 7, 2025.

IDEXX Laboratories, Inc. reported a solid first quarter for 2025, with total revenue growing 3.6% to $998.4 million compared to the prior year. This growth was primarily driven by a 4.7% increase in organic revenue, demonstrating continued underlying business strength, particularly within the Companion Animal Group (CAG) segment. The company also maintained healthy profitability, with income from operations rising 5.9% to $316.5 million and a gross profit margin improvement to 62.4%. Significant stock repurchases were undertaken during the quarter, indicating a commitment to returning capital to shareholders, although this also contributed to a decrease in cash and cash equivalents. While the company navigated some headwinds, including foreign currency fluctuations which negatively impacted revenue growth by 1.2%, the overall financial performance appears robust. Management expects continued growth, supported by new business gains, customer retention, and strategic investments in product development. The company also successfully managed its debt levels, maintaining compliance with its leverage ratio covenants, and has sufficient liquidity to fund operations and growth initiatives for the foreseeable future.

IDEXX Laboratories, Inc. (IDXX) has filed a Form 8-K on May 1, 2025, to report its financial results for the first quarter ended March 31, 2025. The filing primarily consists of a press release announcing these results, which is furnished as an exhibit. Investors should note that while this report provides key financial performance indicators, the information is furnished and not deemed "filed" for regulatory purposes, meaning it doesn't carry the same legal implications as a fully filed document under Section 18 of the Exchange Act. This announcement is critical for stakeholders seeking to understand the company's recent performance and its trajectory for the remainder of the fiscal year. While the specific financial figures and operational details are contained within the attached press release (Exhibit 99.1), this 8-K filing serves as the official notification of their availability. Investors are encouraged to review the press release for a comprehensive understanding of the quarter's results, including revenue, earnings, and any forward-looking guidance provided by the company.

IDEXX Laboratories, Inc. (IDXX) reported solid financial performance for the fiscal year ended December 31, 2024, characterized by continued revenue growth and expanding gross profit margins. The company's primary segment, the Companion Animal Group (CAG), demonstrated resilience, with recurring diagnostic revenue comprising approximately 80% of consolidated revenue, highlighting the strength of its business model. Despite macroeconomic headwinds and sector-specific challenges such as reduced veterinary clinic capacity, IDEXX achieved organic revenue growth driven by price realization and steady customer retention. The company also saw growth in its Water business, while the Livestock, Poultry, and Dairy (LPD) segment remained largely stable. Investments in Research and Development remain a priority, with a focus on integrating Artificial Intelligence (AI) into its product and service offerings. Financially, IDEXX reported an increase in income from operations and maintained a strong gross profit margin of 61.0%. While operating expenses, particularly general and administrative costs due to litigation, saw an increase, the overall financial health appears robust. The company actively manages its capital structure, including share repurchases and maintaining a strong liquidity position with significant available borrowing capacity under its credit facility. IDEXX is well-positioned to continue investing in innovation and expanding its global reach, though it remains mindful of risks related to competition, supply chain disruptions, regulatory changes, and currency fluctuations.

IDEXX Laboratories, Inc. (IDXX) has filed a Form 8-K reporting the immediate resignation of Dr. Asha Collins from its Board of Directors, effective February 13, 2025. The company explicitly states that Dr. Collins' departure was not due to any disagreements regarding the company's operations, policies, or practices. This event has resulted in a reduction of the Board's size from ten to nine directors. The company expressed gratitude for Dr. Collins' contributions during her time on the Board. While this filing does not contain financial results or strategic updates, the departure of a director, even under amicable circumstances, is a noteworthy event for investors. It may prompt questions about board composition, governance, and any potential implications for future decision-making. Investors should monitor future filings for any information regarding the replacement of Dr. Collins or changes in board committee memberships.

IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report on February 3, 2025, to announce its financial results for the fourth quarter and full year ended December 31, 2024. The report itself primarily serves to furnish the press release containing these results, which is attached as Exhibit 99.1. Investors should refer to the press release for detailed financial performance, operational achievements, and forward-looking statements. This filing indicates that the company has met its reporting obligations by disclosing its latest financial outcomes. While the 8-K itself is a procedural filing, the accompanying press release is expected to provide critical insights into IDEXX's revenue growth, profitability, segment performance (such as diagnostics and software), and any strategic updates or outlook for the upcoming fiscal year. Investors will be keen to understand how the company performed against expectations and its long-term growth trajectory.

IDEXX LABORATORIES INC /DE (IDXX) announced on December 11, 2024, the adoption of a new Nonqualified Deferred Compensation Plan, effective December 6, 2024. This plan allows a select group of management and highly compensated employees to voluntarily defer a portion of their base salary, annual bonus, and Stock Units. The primary purpose of this plan is to provide tax-advantaged savings opportunities for key personnel, aligning with Section 409A of the Internal Revenue Code. While the company has no current intention to make discretionary contributions, the plan allows for such contributions in the future, with specific vesting conditions. Distributions can occur upon separation from service, specified dates, death, or unforeseen emergencies, with settlement typically in cash, except for Stock Unit deferrals which will be settled in company common stock. This initiative aims to enhance executive compensation and retention strategies by offering a flexible and tax-efficient way for participants to save for the future.

IDEXX Laboratories, Inc. (IDXX) announced on December 9, 2024, a significant expansion of its share repurchase program. The Finance Committee of the Board of Directors authorized the repurchase of up to five million additional shares of common stock. This move indicates management's confidence in the company's financial health and its commitment to returning value to shareholders. The new authorization is in addition to the 1.3 million shares remaining under the existing program, substantially increasing the capital available for buybacks. These repurchases can be executed through various methods, including open market transactions and Rule 10b5-1 plans, providing flexibility for management. The program has no expiration date and can be adjusted as needed, signaling a potentially ongoing effort to manage its share count. Investors should view this as a positive signal of capital discipline and shareholder return strategy, potentially supporting the stock price.

IDEXX Laboratories, Inc. (IDXX) announced a significant leadership transition for its Chief Financial Officer role. Brian P. McKeon, who has served as Executive Vice President, Chief Financial Officer, and Treasurer since 2014, will retire effective June 1, 2025. Mr. McKeon will transition from his CFO duties on March 1, 2025, to serve as a Special Advisor to ensure a smooth handover. The company has appointed Andrew Emerson, currently Senior Vice President of Finance for the Companion Animal Group (CAG) and Corporate Finance, to succeed Mr. McKeon as Executive Vice President, Chief Financial Officer, and Treasurer, effective March 1, 2025. Mr. Emerson brings extensive finance experience within IDEXX and prior to that at Medtronic. This transition is a key event for investors to note, as financial leadership continuity and compensation packages are crucial for evaluating company strategy and performance.

IDEXX LABORATORIES INC /DE (IDXX) filed an 8-K on November 11, 2024, reporting a significant change in its Board of Directors. Jonathan W. Ayers, a long-serving former executive and director, resigned from the Board and its finance committee effective November 8, 2024. The company stated that Mr. Ayers's departure was not due to any disagreements regarding company operations, policies, or practices. Mr. Ayers had a substantial tenure with IDXX, having served as Chairman, President, and CEO from 2002 to 2019, and as a non-employee director until his recent resignation. The Board expressed gratitude for his over two decades of service and contributions. Following his resignation, the size of the Board has been reduced from eleven to ten directors. The filing also includes his resignation letter as an exhibit.

IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report to disclose amendments to its material definitive agreements concerning the supply of dry slides for its veterinary chemistry analyzers. These amendments, effective October 31, 2024, extend the supply agreements with Ortho-Clinical Diagnostics, Inc. through the end of 2044 for both U.S. and European operations. The key changes involve a significant extension of the contract expiration dates and modifications to the pricing structures, including adjustments to volume tiers and associated pricing over the extended contract terms. These amendments are crucial for ensuring the continued supply of a critical component for IDEXX's diagnostic instruments, providing long-term operational stability and predictability.

IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report on October 31, 2024, to announce its financial results for the third quarter ended September 30, 2024. The report primarily serves to furnish the company's earnings press release, which contains the detailed financial performance and operational updates for the period. Investors should refer to Exhibit 99.1 for the complete earnings announcement. This filing does not contain new financial statements or significant operational changes beyond what is disclosed in the accompanying press release. The information furnished is for informational purposes and is not deemed "filed" for purposes of Section 18 of the Exchange Act, unless specifically incorporated by reference into other filings. The Chief Financial Officer, Brian P. McKeon, signed the report.

IDEXX Laboratories, Inc. (IDXX) has filed an amendment to its prior 8-K filing, specifically to correct an error in its previously issued earnings release from October 31, 2024. The amendment pertains to the company's financial outlook for the full year 2024. Investors should note that the projected range for comparable operating profit margin expansion has been revised downwards. The original earnings release projected a 70 to 100 basis point expansion, but this amendment clarifies that the actual expected range is now 30 to 60 basis points. All other financial results and forward-looking statements from the original release remain unchanged. This revision suggests a recalibration of the company's internal profit margin targets for the remainder of the fiscal year.

IDEXX Laboratories, Inc. reported strong third-quarter results, demonstrating robust revenue growth driven by its core Companion Animal Group (CAG) segment. Total revenue increased by 6.6% year-over-year to $975.5 million, with organic revenue growing by 6.1%, highlighting the company's ability to drive growth through a combination of price realization and volume increases across its diagnostic consumables and services. The company maintained healthy profitability, with gross profit margin improving to 61.1% and operating income rising by 10.4% to $303.9 million. This financial performance was supported by effective cost management and favorable business mix, despite ongoing inflationary pressures. IDEXX also continues to execute its capital allocation strategy, with significant share repurchases and investments in growth, while maintaining a strong liquidity position and compliance with financial covenants.

IDEXX Laboratories, Inc. reported solid revenue growth for the second quarter of 2024, driven primarily by its Companion Animal Group (CAG) segment, which saw increases in diagnostics recurring revenue, supported by price realization and volume growth. Overall revenue for the quarter increased by 6.4% year-over-year to $1.004 billion. While operating income saw a decline of 10.9% to $263.8 million, this was largely due to a significant $61.5 million expense related to an ongoing litigation matter. Excluding this one-time charge, the company demonstrated continued operational strength and profitability. The company's balance sheet remains robust, with total assets growing to $3.41 billion. While cash and cash equivalents decreased slightly to $401.6 million from $453.9 million at the end of 2023, this was primarily due to strategic uses of cash, including significant share repurchases totaling $370.3 million in the first six months of 2024. The company maintains substantial liquidity with $998.5 million in unused borrowing capacity under its credit facility, indicating strong financial flexibility. Investors should note the ongoing litigation accrual as a significant factor influencing near-term profitability.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on August 6, 2024, to report its financial results for the second quarter ended June 30, 2024. The core of this filing is the press release (Exhibit 99.1) containing the detailed financial performance for the period. Investors should refer to this press release for specific figures related to revenue, profitability, and any forward-looking statements or guidance provided by the company. This filing serves as the official channel for disseminating these results, making the press release a crucial document for understanding IDXX's recent operational and financial standing. While the 8-K itself is procedural, the furnished press release contains the substance of the company's performance updates, which are essential for investment analysis and decision-making. Investors are encouraged to review Exhibit 99.1 for a comprehensive understanding of IDXX's Q2 2024 performance.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on May 9, 2024, detailing two primary events: a consulting agreement with a former executive and the results of its 2024 annual shareholder meeting. Effective May 7, 2024, James F. Polewaczyk, formerly an Executive Vice President who retired on April 1, 2024, entered into a one-year consulting agreement. Under this agreement, Mr. Polewaczyk will provide coaching and professional development support to select employees for a fee of $25,000 per month. The annual meeting, held on May 6, 2024, saw shareholders approve all presented proposals. Key outcomes include the election of four Class I directors, the ratification of PricewaterhouseCoopers LLP as the independent registered accounting firm, and an advisory vote to approve executive compensation. Additionally, a shareholder proposal regarding simple majority vote was put to a vote and was approved by a majority of shareholders.

IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K on May 1, 2024, to announce its financial results for the quarter ended March 31, 2024. The report primarily furnishes a press release detailing these results, which is attached as Exhibit 99.1. Investors should note that this information, while crucial for understanding the company's performance, is being furnished under Item 2.02 and is not considered "filed" for purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal implications of filed documents unless specifically incorporated by reference into other filings. The core of this filing is the attached press release, which provides the company's operational and financial outcomes for the first quarter of 2024. While the 8-K itself is a procedural document, investors are advised to refer to the furnished press release (Exhibit 99.1) for the specific financial metrics, performance trends, and any forward-looking statements or management commentary related to the quarter's results. The filing also lists the Chief Financial Officer and Treasurer as signing for the company, indicating the official release of this information.

IDEXX Laboratories, Inc. reported solid financial results for the first quarter of 2024, with total revenue reaching $964.1 million, a 7.1% increase year-over-year. This growth was primarily driven by its core Companion Animal Group (CAG) segment, which saw a 7.5% revenue increase, largely due to higher recurring revenue from diagnostics, consumables, and veterinary software and services. The company also demonstrated improved profitability, with gross profit rising 9.2% and income from operations increasing 6.6% to $299 million, reflecting an expanded gross margin of 61.5% compared to 60.3% in the prior year, aided by favorable sales mix and pricing. While the company continues to invest in growth, evidenced by a rise in R&D and G&A expenses, its financial position remains strong. Net income increased by 10.1% to $235.6 million, resulting in diluted EPS of $2.81, up from $2.55 in the prior year. The company also maintained a healthy liquidity position, with $397.4 million in cash and cash equivalents and significant borrowing availability under its credit facility. Notably, IDEXX repurchased $154.8 million of its common stock during the quarter, signaling confidence and a commitment to returning value to shareholders. The company expects continued growth, though it acknowledges potential headwinds from macroeconomic conditions and foreign currency fluctuations.

IDEXX Laboratories, Inc. (IDXX) reported solid performance in its 2023 10-K filing, driven primarily by its Companion Animal Group (CAG). The company demonstrated robust revenue growth, with a notable increase in recurring revenues from consumables and services. This segment's strength, fueled by the ongoing demand for advanced veterinary diagnostics and information management solutions, significantly contributed to the overall financial health of the company. While the CAG segment showed strong organic growth, the Water segment also experienced positive revenue increases due to price adjustments and volume growth, bolstered by a strategic acquisition. The Livestock, Poultry, and Dairy (LPD) segment saw a slight revenue decline, influenced by external factors like reduced live animal imports. The 'Other' segment, primarily comprising human medical diagnostics, experienced a significant revenue drop due to the discontinuation of COVID-19 testing products. Overall, IDEXX continues to leverage its integrated diagnostic solutions and software offerings to enhance veterinary practice efficiency and patient care, positioning itself for continued success in the animal health market.

IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K on February 5, 2024, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2023. The report itself is brief, acting as a cover for the more detailed press release furnished as Exhibit 99.1. Investors should refer to this press release for comprehensive details on the company's performance, including key financial metrics, operational achievements, and any forward-looking statements or guidance.

IDEXX Laboratories, Inc. (IDXX) announced on December 5, 2023, that its Executive Vice President and Chief Commercial Officer, James F. Polewaczyk, will retire effective April 1, 2024. Mr. Polewaczyk has served the company in leadership capacities for over 17 years, contributing significantly to its commercial operations and growth. This departure marks the end of a long tenure for a key executive. Investors will likely want to understand the succession plan for this critical role and how Mr. Polewaczyk's departure might impact the company's commercial strategy and execution moving forward. While the filing does not provide details on a successor, it indicates a planned transition, allowing time for leadership to address this change.

IDEXX Laboratories Inc. (IDXX) reported strong financial results for the nine months ended September 30, 2023, with total revenue increasing by 8.7% to $2.76 billion and net income attributable to stockholders rising by 28.3% to $650.5 million, or $7.75 per diluted share. The Companion Animal Group (CAG) segment remains the primary revenue driver, showing robust growth across its recurring revenue streams, including consumables, diagnostics, and software services. The company also demonstrated solid cash flow generation, with operating activities providing $656.7 million, enabling significant debt reduction and strategic investments. Despite a challenging macroeconomic environment, IDEXX's diversified business model and focus on recurring revenue streams have proven resilient. The company successfully managed operational costs, leading to improved gross profit margins and overall profitability. While international revenue growth showed some moderation, the U.S. market remained a strong performer. Looking ahead, IDEXX is well-positioned to continue its growth trajectory, supported by its strong market position, ongoing innovation, and disciplined capital allocation.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on November 1, 2023, to report its financial results for the third quarter ended September 30, 2023. The report primarily serves to furnish the press release detailing these results, which provides investors with the company's latest performance metrics. Specific financial figures and operational highlights are contained within the furnished press release (Exhibit 99.1), which is the key document for investors to review for detailed insights into the company's performance during the quarter. While the 8-K itself does not contain the detailed financial data, it officially announces the availability of IDEXX's third-quarter results. Investors seeking to understand the company's revenue, profitability, segment performance, and any forward-looking statements or guidance should refer to the press release attached as Exhibit 99.1. This filing signifies the company's adherence to timely disclosure requirements regarding its financial condition and operational outcomes.

IDEXX Laboratories, Inc. reported solid financial results for the second quarter of 2023, demonstrating robust revenue and income growth. Total revenue increased by 9.7% year-over-year to $943.6 million, driven primarily by strong performance in the Companion Animal Group (CAG) segment, which saw a 10.5% increase in revenue. This growth was fueled by recurring diagnostics revenue, higher realized prices globally, and increased volumes in the U.S. Net income attributable to IDEXX stockholders grew significantly by 69.9% to $224.2 million, or $2.67 per diluted share. This substantial increase reflects improved gross margins, driven by pricing strategies and operational efficiencies, as well as a significant decrease in research and development expenses compared to the prior year's acquisition-related costs. The company maintained a strong balance sheet with increased cash and cash equivalents and a healthy liquidity position, underscored by a significant available borrowing capacity under its credit facility.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on August 1, 2023, primarily to announce its financial results for the second quarter ended June 30, 2023. While the filing itself is brief, it directs investors to a furnished press release (Exhibit 99.1) for the detailed financial performance and operational updates. This is a standard disclosure for earnings announcements, indicating that the company's performance metrics are available for investor review through the accompanying press release.

IDEXX Laboratories, Inc. (IDXX) announced a change in its Board of Directors through an 8-K filing on July 12, 2023. The company elected Irene Chang Britt as an independent Class I Director, effective July 11, 2023. This appointment also includes her joining the Audit Committee and the Compensation and Talent Committee. To accommodate this addition, the size of the Board has been expanded from ten to eleven directors, with the number of Class I Directors increasing from three to four. Ms. Chang Britt's appointment is notable as she has no disclosed related-party transactions. Her compensation will align with that of other non-employee directors, with adjustments reflecting recent increases in annual retainers and equity awards approved in May 2023. Specifically, her annual cash retainer will be $90,000, and her annual equity compensation will be valued at $250,000, split evenly between full-value awards and stock options. These will be prorated to reflect her service period from July 11, 2023, to the 2024 annual meeting. The company also issued a press release on July 12, 2023, to announce this board change.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K report detailing the results of its 2023 Annual Meeting of Shareholders, held on May 17, 2023. The primary purpose of this filing was to report the voting outcomes on several key proposals. Investors should note that all proposed items, including the election of three Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and advisory votes on executive compensation and its frequency, received majority shareholder approval. The election of directors Daniel M. Junius, Lawrence D. Kingsley, and Sophie V. Vandebroek was successful, with significant "For" votes compared to "Against" and "Abstain" votes, ensuring continued board leadership. Shareholders also overwhelmingly ratified the appointment of PricewaterhouseCoopers LLP, indicating confidence in their financial oversight. Furthermore, the advisory vote to approve executive compensation passed, and the company will hold an advisory vote on executive compensation annually, as decided by the shareholders.

IDEXX Laboratories, Inc. (IDXX) reported solid financial results for the first quarter of 2023, demonstrating continued growth driven by its Companion Animal Group (CAG) segment. Total revenue increased by 7.6% year-over-year to $900.2 million, with organic revenue growth of 9.8%, reflecting strong performance in recurring revenue, price increases, and software/service offerings. Despite some headwinds in the LPD and Other segments, the company's overall profitability improved, with a 12.9% increase in income from operations to $280.4 million. The company also showed progress in managing its financial resources, evidenced by a significant increase in operating cash flow and a reduction in credit facility borrowings. While facing inflationary pressures impacting cost of revenue and operating expenses, IDEXX maintained its focus on strategic investments in growth initiatives, particularly within its core CAG segment. The company's financial position remains strong, with ample liquidity and a conservative leverage ratio, positioning it well for future growth and resilience.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on May 2, 2023, to report its financial results for the first quarter ended March 31, 2023. While the 8-K itself is a brief filing, it serves as a notification that the company has released its detailed financial performance in an accompanying press release, furnished as Exhibit 99.1. Investors should refer to the press release for comprehensive details on revenue, earnings, and any forward-looking guidance. This 8-K filing primarily signals the availability of these crucial Q1 2023 financial updates and does not contain new substantive operational or financial data within the 8-K document itself.

IDEXX Laboratories Inc. reported solid revenue growth of 4.7% to $3.37 billion for the fiscal year ended December 31, 2022. This growth was primarily driven by the Companion Animal Group (CAG), which saw an 8.4% organic revenue increase, demonstrating continued demand for veterinary diagnostics and services. Despite a slight decrease in clinical visits, revenue per practice grew, highlighting increased utilization of diagnostic products. The Water segment also showed positive organic growth of 9.7%. However, the Livestock, Poultry, and Dairy (LPD) segment experienced a decline, largely due to reduced demand in China for swine testing. Research and development expenses saw a significant increase (58.3%) due to strategic investments in technology licensing. The company highlighted its strong gross profit margin of 59.5%, supported by price gains and efficiency initiatives, though facing increased costs in freight, distribution, and labor. IDEXX also actively managed its capital through share repurchases and a $1.25 billion credit facility, ending the year with $112.5 million in cash and cash equivalents. The company remains focused on innovation, customer relationships, and operational efficiency to navigate a competitive landscape and maintain long-term value creation for shareholders.

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on February 6, 2023, to announce its financial results for the fourth quarter and full year ended December 31, 2022. The report primarily furnishes the press release detailing these results, which should be reviewed for comprehensive financial and operational information. Investors should note that this information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act, meaning it does not carry the same liability implications, nor is it automatically incorporated into other filings unless specifically referenced. The core of this filing is the attached press release (Exhibit 99.1), which provides the quantitative and qualitative details of IDEXX's performance. While the 8-K itself does not contain the detailed financial statements or operational analysis, it serves as the official notification mechanism for the market to access this crucial information directly from the company. Investors seeking to understand IDEXX's recent financial health and operational standing are directed to review the furnished press release.

IDEXX LABORATORIES INC /DE (IDXX) reported its third-quarter and nine-month results for the period ending September 30, 2022. The company demonstrated solid revenue growth, driven primarily by its Companion Animal Group (CAG) segment. Total revenue for the nine months increased to $2.54 billion, a 5.2% rise compared to the prior year, with organic revenue growth of 7.5% excluding currency impacts and acquisitions. While net income saw a decrease for the nine-month period, primarily due to increased research and development investments, the company maintained strong operational performance and a healthy gross profit margin. Looking ahead, IDEXX is navigating supply chain challenges and foreign currency headwinds but remains strategically positioned for continued growth, particularly within the companion animal healthcare market. The company's liquidity remains robust, supported by operating cash flows and available credit facilities, enabling ongoing investments in innovation and strategic acquisitions.

IDEXX Laboratories, Inc. (IDXX) filed a Form 8-K on November 1, 2022, to report its financial results for the third quarter ended September 30, 2022. The filing primarily serves as a notification of the earnings release, which is furnished as an exhibit. Investors should refer to the press release (Exhibit 99.1) for detailed financial performance and operational updates for the quarter. This report itself does not contain the specific financial figures but points investors to the official announcement for that information.

IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report detailing an amendment to its existing $1.0 billion unsecured revolving credit facility. This amendment, effective October 20, 2022, introduces significant changes, including the immediate borrowing of $250 million in incremental term loans. Furthermore, the company has transitioned its existing LIBOR-based borrowings to SOFR-based interest rates, aligning with industry-wide shifts away from LIBOR. The amendment also provides IDEXX with the flexibility to potentially increase its total credit facility to up to $1.5 billion, subject to securing additional commitments from lenders. This strategic move enhances the company's financial flexibility and provides resources for general corporate purposes. The amendment outlines updated interest rate structures for various currencies, primarily referencing SOFR for USD borrowings, and includes customary covenants and events of default.